NCT06886009View on ClinicalTrials.gov

Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis

Not yet recruitingOBSERVATIONAL
Enrollment

21

Participants

Timeline

Start Date

November 28, 2025

Primary Completion Date

June 8, 2029

Study Completion Date

June 8, 2029

Conditions
Generalized Pustular Psoriasis
Interventions
DRUG

Spevigo®

Intravenous

Trial Locations (4)

16499

Ajou University Hospital, Gyeonggi-do

49241

Pusan National University Yangsan Hospital, Busan

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY